Latest edition: 22 August 2024
Latest edition: 22 August 2024
The issue at a third-party manufacturer has been resolved, with an FDA re-inspection now planned.
Valued at approximately $30m, the deal contributes to Emergent’s financial recovery plan amid its dramatic post-Covid decline.
The company halted the Phase II trial of its mTOR inhibitor after an independent analysis found that it would not meet the efficacy threshold.
GLP1R agonists are currently used for the treatment of type 2 diabetes (T2D) and obesity to stimulate insulin secretion and inhibit glucagon release.
The sBLA submission is supported by results from the Phase III CheckMate 9DW trial.
The funds will support Pathalys’ lead candidate upacicalcet through two clinical trials and potentially accelerate its approval.
Dupert is approved for NSCLC treatment in adults with the KRAS G12C mutation.
University of Nottingham scientists are scaling up development of a Zika virus DNA vaccine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
